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Chronic inﬂammation has emerged as one of the hallmarks of cancer. Inﬂammation also
plays a pivotal role in modulating radiation responsiveness of tumors. As discussed in this
review, ionizing radiation (IR) leads to activation of several transcription factors modulating
the expression of numerousmediators in tumor cells and cells of themicroenvironment pro-
moting cancer development. Novel therapeutic approaches thus aim to interfere with the
activity or expression of these factors, either in single-agent or combinatorial treatment or
as supplements of the existing therapeutic concepts. Among them, NF-κB, STAT-3, and HIF-
1 play a crucial role in radiation-induced inﬂammatory responses embedded in a complex
inﬂammatory network. A great variety of classical or novel drugs including nutraceuticals
such as plant phytochemicals have the capacity to interfere with the inﬂammatory network
in cancer and are considered as putative radiosensitizers.Thus, targeting the inﬂammatory
signaling pathways induced by IR offers the opportunity to improve the clinical outcome of
radiation therapy by enhancing radiosensitivity and decreasing putative metabolic effects.
Since inﬂammation and sex steroids also impact tumorigenesis, a therapeutic approach
targeting glucocorticoid receptors and radiation-induced production of tumorigenic factors
might be effective in sensitizing certain tumors to IR.
Keywords: radiation, inflammation, radioresistance, PGHS-2, heat shock proteins, NF-κB, STAT-3, HIF-1
INTRODUCTION
Chronic inﬂammation has emerged as one of the hallmarks
of cancer impacting any stage of tumorigenesis (Colotta et al.,
2009; Grivennikov and Karin, 2010). The persistent expression of
inﬂammatory mediators exert pleiotropic effects on the malig-
nant process. On the one hand, they affect carcinogenesis and
malignant transformation, tumor growth, invasion, and metasta-
sis, on the other hand they activate immune effector mechanisms
limiting tumor growth. The link between cancer and inﬂamma-
tion can be viewed as consisting of two pathways: an intrinsic
and an extrinsic pathway (Mantovani et al., 2008). At the level of
the tumor cell, both pathways converge and induce the activation
of several transcription factors culminating in the formation of
numerous pro-inﬂammatory molecules that recruit and activate
various leukocyte populations into the tumor microenvironment
(for a review, see Multhoff et al., 2012). The tumor cell-derived
pro-inﬂammatory molecules now activate the same transcription
factors within the cells of the microenvironment and the tumor
cells themselves resulting in a more pronounced generation of
inﬂammatory mediators driving a tumor-promoting ampliﬁca-
tion loop. This ampliﬁcation mechanism further enhances the
impact of inﬂammatory stimuli within the tumor environment
and triggers the manifestation of a cancer-related inﬂammatory
milieu contributing to tumor growth and invasiveness.
NF-κB provides a mechanistic link between inﬂammation, car-
cinogenesis, and tumor radioresistance (Magne et al., 2006; Ben-
Neriah and Karin, 2011). NF-κB is regarded as the key orchestrator
controlling the ability of both, preneoplastic and malignant cells,
to resist apoptosis-based tumor surveillancemechanisms activated
by DNA damage and chromosomal rearrangement or anti-cancer
drugs and radiation, respectively.NF-κBmight also regulate tumor
angiogenesis and invasiveness (Karin, 2006), and may contribute
to the characteristic radio-/chemoresistance of tumor cells (Fahy
et al., 2004; Singh and Khar, 2006; Antoon et al., 2011; Chaturvedi
et al., 2011). In conjunction with STAT-3 and HIF-1,NF-κB serves
as a modulator of the expression of several factors promoting
cancer development. Novel therapeutic approaches thus aim to
interfere with the activity or expression of these factors, either
in single-agent or combinatorial treatment or as supplements of
the existing therapeutic concepts. Noteworthy, targeting the pro-
inﬂammatory signaling pathways for tumor radiosensitization
represents a promising novel therapeutical approach in cancer.
A great variety of classical or novel drugs including nutraceuticals
have the capacity to interfere with the inﬂammatory network in
cancer and are progressively tested for tumor radiosensitization.
Accumulating evidence over the last few years indicate that most
chemotherapeutic agents and radiation therapy activate NF-κB
(Wang et al., 1996; Sandur et al., 2009; Li and Sethi, 2010). Thus,
NF-κBblockagehas been recognized as apromising tool in increas-
ing radiosensitivity of tumors. Apart from NF-κB, STAT-3, HIF-1,
and PGHS-2 are further inﬂammatory factors crucially involved
in radioresistance of tumors. Thus, interrupting the inﬂammatory
network in cancer by targeting these molecules may be a promis-
ing radiosensitization approach in cancer therapy. Table 1provides
an overview on natural and (semi-)synthetic compounds that are
considered as putative radiosensitizers.
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Table 1 | Natural and (semi-)synthetic compounds as putative radiosensitizers und their targets.
Compound Source/systematic name Target
Anacardic acid Anacardium occidentale (cashew nuts) IKK, NF-κB
Berberine Berberis aristata (Indian barberry, tree turmeric) NF-κB
Butein Rhus verniciﬂua (Chinese lacquer tree) NF-κB
Caffeic acid phenethyl ester Honeybee propoplis GSH, NF-κB
Celecoxib 4-[5-(4-methylphenyl)-3-(triﬂuoromethyl) pyrazol-1-yl]benzenesulfonamide PGHS-2, NF-κB
Cepharanthine Stephania cepharantha Hayata NF-κB, STAT-3
Crotepoxide Kaempferia pulchra (peacock ginger) TAK-1
Curcumin Curcuma longa (turmeric) Akt, IKK, NF-κB
Daidzein, genistein Glycine max (soy bean) STAT-3, HIF-1α
Deguelin Derris trifoliata (threeleaf derris) Hsp90, HIF-1α
EGCG Camellia sinensis (green tea) NF-κB
Emodin Rheum rhabarbarum (Rhubarb), Aloe vera HIF-1
Erufosine Alkylphosphocholine (synthetic phospholipid analog) Akt
Ethaselen 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane; BBSKE Thioredoxin reductase, NF-κB
Flavopiridol Semi-synthetic ﬂavonoid based on an extract from the Indian plant, Dysoxylum
binectariferum
CDKs, cyclin D1, Rb, Bcl-2
Geldanamycin Naturally occurring ansamycin antibiotic from Streptomyces hygroscopicus Hsp90
KNK437 Benzylidene lactam compound Hsp27, Hsp70
Nitidine chloride Zanthoxylum nitidum (Tez-mui, Tejamool in Assamese; locally called
“liangmianzhen”)
STAT-3
Oleandrin Nerium oleander (nerium) Caspase-3
Parthenolide Tanacetum parthenium (feverfew) NF-κB, p53
Piceatannol Hydroxylated resveratrol analog found in various plants, e.g., Vitis spec. NF-κB
Picroliv Picrorhiza kurroa (katuka) NF-κB
Piperine Piper nigrum (black pepper) CYP450 enzymes
Plumbagin Plumbago rosea (Scarlet leadwort) NF-κB
Resveratrol Vitis spec. (grape, red wine) STAT-3, NF-κB
Silymarin Silybum marianum (milk thistle) NF-κB
Xanthohumol Humulus lupulus (common hop) NF-κB
GENETIC INSTABILITY
Recent observations allow a deeper insight into the molecular
and cellular mechanisms linking inﬂammation and tumorigen-
esis. Emerging data suggest that genetic destabilization of tumor
cells is regarded as a further hallmark of most human cancers
contributing to tumor initiation and progression (Colotta et al.,
2009). Apart from the production of cytokines, chemokines, pro-
teases and prostanoids, inﬂammatory cells are able to produce
reactive oxygen species (ROS) and reactive nitrogen species (RNS).
Leukocytes are the main source of RNS and ROS acting as chem-
ical effectors in inﬂammation-driven carcinogenesis (Kundu and
Surh, 2008). All of these mediators act together in perpetuating
and amplifying the inﬂammatory cascade. As outlined in Figure 1,
they suppress DNA repair mechanisms leading to an increase
in genetic instability termed microsatellite instability (MSI) as a
result of mutations or epigenetic alterations of members of the
mismatch repair (MMR) family (Hakem, 2008). The MMR sys-
tem is strongly affected by inﬂammatory conditions. It has been
shown previously that the transcription factor HIF-1 is induced in
tumor cells not only by different cytokines and prostaglandins
(Jung et al., 2003) but also by ROS and RNS (Sandau et al.,
2000). HIF-1 is a heterodimeric transcription factor consisting
of a constitutively expressed β-subunit and an oxygen-regulated
α-subunit (Kaelin Jr. and Ratcliffe, 2008). It was proved that HIF-
1 plays a pivotal role in hypoxia-induced tumor radioresistance
(Moeller and Dewhirst, 2006; Harada, 2011). In this context, our
own investigations revealed no correlation between basal HIF-1α
levels and the survival fraction in irradiated tumor cell lines imply-
ing that basalHIF-1α levels in human tumor cell lines obviously do
not predict their radiosensitivity under normoxia (Schilling et al.,
2012a). Moreover,HIF-1α has been found as being responsible for
genetic instability to down-regulated MMR proteins by inhibiting
the MMR proteins MSH-2 and MSH-6, thereby decreasing lev-
els of the MSH-2/MSH-6 complex, MutSα, which recognizes base
mismatches. HIF-1α displaces the transcriptional activator c-Myc
from Sp1 binding to repress MutSα expression in a p53-dependent
manner (Koshiji et al., 2005). Chang et al. (2002) observed that
hydrogen peroxide inactivates members of the MMR family at
the protein level. From this observation the authors speculate
that inactivation of the MMR function in response to oxidative
stress may be responsible for the low-frequency MSI (MSI-L)
seen in non-neoplastic and cancer tissues associated with chronic
inﬂammation.
Chromosomal instability can also be the result of the deleteri-
ous action of inﬂammatory mediators culminating in abnormal
chromosomal segregation and aneuploidy. The deleterious actions
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FIGURE 1 | Inflammation-induced molecular pathways causing
genetic instability in cancer cells. Genetic destabilization of tumor
cells is regarded as a further hallmark of most human cancers
contributing to tumor initiation and progression. Apart from the
production of cytokines, chemokines, proteases, and prostanoids,
inﬂammatory cells are able to produce reactive oxygen (ROS) and
nitrogen species (RNS). All of these mediators act together in
perpetuating and amplifying the inﬂammatory cascade. On the one
hand, they suppress DNA repair mechanisms leading to microsatellite
instability. On the other hand, they can cause chromosomal instability
culminating in abnormal chromosomal segregation and aneuploidy.
These inﬂammatory mediators induce DNA double-strand breaks, affect
function of mitotic checkpoint molecules and dysregulate homologous
recombination of DNA double-strand break repair leading to random
genetic diversiﬁcation of tumor cells. Cancer cells harboring the optimal
combination of activated oncoproteins and inactivated oncosuppressor
proteins will develop the malignant phenotype (ﬁgure adapted from
Colotta et al., 2009; for details see text).
of inﬂammatory mediators include direct or indirect induction of
DNA double-strand breaks (Karanjawala et al., 2002; Mills et al.,
2003), defective mitotic checkpoints (Rajagopalan et al., 2003;
Menssen et al., 2007), and dysregulated homologous recombina-
tion of DNA double-strand break repair (Saintigny et al., 2001;
Hakem,2008; Plo et al., 2008). Further criticalmolecules that affect
genetic stability comprise activation-induced cytidine deaminase
(AID; Endo et al., 2008), c-Myc (Vafa et al., 2002), phospho-
retinoblastoma protein pRb (Pickering and Kowalik, 2006), and
p53 (Tomasini et al., 2008). By causing microsatellite as well as
chromosomal instability these molecules induce random genetic
diversiﬁcation of tumor cells. As already discussed by Colotta
et al. (2009), cancer clones harboring the optimal combination
of activated oncoproteins and inactivated oncosuppressors will
develop the malignant phenotype (Figure 1).
CELL–CELL INTERACTIONS
In the tumor microenvironment, an intensive interaction between
tumor cells and inﬁltrating immune cells occurs. The latter com-
prise macrophages, dendritic cells (DC), T cells as well as NK cells
withmacrophages andTcells as being themost frequent ones (Lus-
ter et al., 2005). Inﬂammatory mediators secreted by tumor and
immune cells have been found to play a dual role in tumor devel-
opment. On the one hand, they promote tumor development and
survival of tumor cells, on the other hand they exert surveillance
mechanisms against tumor cells (Ben Baruch, 2006; Kim et al.,
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2006b). In case of a predominance in anti-tumor immunity, tumor
cells are eradicated whereas a predominance in surveillance mech-
anisms provides cancer cells with an immunosuppressive network
extending the immune evasion and promoting tumor progression
and metastasis (Hadden, 2003). Among the inﬂammatory medi-
ators secreted by tumor and immune cells TNF, IL-6, and IL-17
act as crucial players in developing chronic inﬂammation result-
ing in immune escape and acceleration of tumor progression and
metastasis. Upon activation, myeloid cells produce pro- and anti-
inﬂammatory mediators not only affecting growth, survival, and
invasiveness of tumor cells but also controlling functional activi-
ties of Th1,NK,Treg, andTh17 cells (Lin andKarin, 2007). TRAIL,
a member of the TNF superfamily and the product of activated T
and NK cells, directly induces apoptosis in numerous cancer cells
(LeBlanc andAshkenazi, 2003) thus playing a crucial role in tumor
surveillance mechanisms. Regulatory T cells (Treg) function as
key components for regulating anti-tumor immunity (Yamaguchi
and Sakaguchi, 2006). Treg speciﬁcally suppress the cytotoxicity of
expanded CD8+ cytotoxic T cells (Chen et al., 2005) and induce
release of IL-17 from Th17 cells acting as key players in chronic
inﬂammation (Mangan et al., 2006). IL-17-mediated effects on
the inﬂammatory response involve recruitment of immune cells
(Park et al., 2005), induction of pro-inﬂammatory factors (IL-1,
IL-6,TNF) aswell as promotion of angiogenesis and tumor growth
(Numasaki et al., 2003). Development of Th17 cells is stimulated
by IL-6, IL-23, TGF-β, and TNF released from activated myeloid
cells. Anti-inﬂammatory IL-10 inhibits tumor progression and
development by blocking synthesis of IL-6, IL-12, and TNF via
NF-κB inhibition (Moore et al., 2001). Furthermore, the anti-
tumor activity of Treg is mediated by IL-10 released from Treg
themselves (Erdman et al., 2003). IL-23 belonging to the IL-12
family of cytokines enhances the production of IFN-γ and IL-12
by activated T cells, induces IL-17 release from Th17 cells and
promotes inﬂammation at its ﬁnal stage (Cho et al., 2006). More-
over, IL-23 has been found to up-regulate expression of MMP-9,
to increase angiogenesis and to decrease CD8+ T cell recruitment
to tumors possibly providing the basis for the development of
a tumor-promoting environment (Langowski et al., 2006). IL-12,
also released fromantigen-presenting cells (APC) after stimulation
with IL-23, is a further member of the IL-12 family of cytokines
and harbors anti-tumor activities in particular via stimulation
of Th1- and CTL-mediated immune responses (Trinchieri, 2003;
Langowski et al., 2006). Table 2 summarizes the cellular and mol-
ecular outcomes based on interactions between various cell types
in the tumor microenvironment.
SEX STEROIDS
An increasing number of data currently reveal the close relation-
ship between the two classical pathways in tumor progression:
inﬂammation and gonadal hormones. Since the discovery of the
hormone dependency of mammary carcinoma in the 1890s, it
has become clear that gonadal steroids play a crucial role in the
pathogenesis of breast and prostate cancer. The Scottish surgeon
George Thomas Beatson was about the ﬁrst who showed that
oophorectomy in a premenopausal woman with breast cancer led
to a complete remission (Beatson, 1896a,b) highlighting the role of
sex steroids in tumor pathogenesis. However, more recent inves-
tigations revealed an astonishing effect of gonadal hormones on
tumorigenesis. Female somatic cells including tumor cells express
receptors for sex steroid hormones such as estrogen and proges-
terone affecting growth of hormone-dependent breast cancer cells
(Henderson and Canellos, 1980a,b). Women are well known as
being less susceptible to tumors at organ sites not representing
classical targets for gonadal hormones including the liver. Thus,
hepatocellular carcinoma (HCC), the most common liver cancer,
occurs mainly in men. The same gender disparity is seen in mice
Table 2 | Effects of cell–cell interactions in the tumor microenvironment.
Effector Molecular/cellular outcome Physiology/pathophysiology
IL-6, IL-10, TNF Enhancement of tumor cell growth Chronic inﬂammation
IL-10 Anti-inﬂammatory, blockage of IL-6, IL-12, TNF synthesis via NF-κB inhibition Tumor suppression
IL-12 Activation of CD8+ CTL and NK cells, expression of cytotoxic mediators (IFN,TRAIL,TGF-β) Anti-tumor effect
IL-17 Induction of pro-inﬂammatory mediators (IL-1, IL-6, TNF) Chronic inﬂammation, tumor
progression
IL-23 Induction of IL-12/IFN-γ release from activatedT cells, TNF/IL-12 from APC, IL-17 fromTh17
cells, MMP-9 up-regulation, decrease of CD8+ CTL recruitment, increase in angiogenesis
Chronic inﬂammation, tumor
progression
TGF-β Enhancement of tumor cell invasiveness and angiogenesis, inhibition of NK cells, CTL,
macrophages
Tumor progression
Anti-inﬂammatory effects onT cells, tumor suppressor/cytotoxic activity Anti-tumor effect
TRAIL Induction of apoptosis Tumor suppression
Treg cells IL-10 release fromTreg, suppression of CD8+ CTL Anti-tumor effect
Induction of IL-17 release fromTh17 Chronic inﬂammation
TNF Promotion of angiogenesis and metastasis, impairment of immune surveillance via T cell
and macrophage blockage
Tumor progression, chronic
inﬂammation
Destruction of tumor vasculature and induction of necrosis Anti-tumor effect
IL-23, TGF-β, IL-6, TNF Th17 cell development Chronic inﬂammation
IL-6, TNF, TGF-β Impact on stromal cells and metastasis Tumor progression
IL-17, TNF Impact on endothelial cells, increase in angiogenesis Tumor growth
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given a chemical carcinogen, diethylnitrosamine (DEN) resulting
in liver parenchymal damage followed by activation of Kupffer
cells (KC; Naugler et al., 2007). As demonstrated in this study,
DEN induces NF-κB-dependent production of pro-inﬂammatory
and growth-promoting IL-6 in KC via IL-1 and TLR signaling cas-
cades, respectively, ﬁnally leading to tumor development. Estrogen
inhibits activation of NF-κB and blocks secretion of IL-6 from KC
thus protecting against liver cancer in females.
Prostate cancer is an androgen-dependent cancer whose sus-
ceptibility to gonadal hormones is regulated by selective androgen-
receptor modulators (SARM) attenuating the proliferative proper-
ties of androgens on tumor cells. Pro-inﬂammatory IL-1 derived
from tumor cells or cells of the microenvironment reverses the
properties of SARM frombeing inhibitory to activatory (Zhu et al.,
2006). This de-repression effect requires TGF-β-activated kinase 1
(TAK-1)-binding protein (TAB) 2 (=TAB-2; Takaesu et al., 2000).
At the molecular level, IL-1 signaling induces phosphorylation of
TAB-2. TAB-2 acts as a sensor for inﬂammatory signals by serving
as a molecular beacon for recruitment of MEKK1, which in turn
mediates dismissal of the nuclear receptor co-repressor (N-CoR)
holoco-repressor complex from the androgen-receptor and per-
mits de-repression of androgen and estrogen receptor target genes.
According to Zhu et al. (2006), this strategy might have come into
notice in order to trigger reversal of gonadal hormone-dependent
repression of a limited cohort of target genes in response to
inﬂammatory signals linking inﬂammatory, and nuclear receptor
ligand responses to essential reproductive functions. Treatment of
prostate cancer by androgen deprivation either by suppression of
testicular androgen production or by the use of pharmacological
SARMsuch as ﬂutamide or bicalutamide remains the standard sys-
temic therapy. It has been shownpreviously that bicalutamide does
not function as an androgen-receptor (AR) antagonist by prevent-
ing AR binding to DNA but instead stimulates the assembly of a
transcriptionally inactive receptor on DNA (Masiello et al., 2002).
Recent reports demonstrate that AR can also bind to co-repressor
proteins, including N-CoR, and that this binding is enhanced in
the presence of bicalutamide indicating that co-repressor binding
could further contribute to the in vivo antagonist activity of bica-
lutamide (Cheng et al., 2002; Shang et al., 2002; Yoon and Wong,
2006). Interestingly, the group of Hollenberg clearly demonstrated
that the AR/N-CoR interaction is not enhanced by AR antagonists
used currently for the treatment of prostate cancer, but can be
markedly enhanced by mifepristone (RU486) in vitro (Hodgson
et al., 2005). RU486 can thus be considered as a novel AR antago-
nist that will likely have novel activities in vivo. However, clinical
trials of RU486 or related drugs are needed to determine whether
these may be more efﬁcacious than currently available AR antag-
onists in the treatment of prostate cancer, particularly advanced
androgen-independent prostate cancer.A recent phase II studywas
conducted to assess the efﬁcacy of mifepristone as an AR antago-
nist in patients with castration-resistant prostate cancer (CRPC).
In this study, RU486 showed only limited activity in patients with
CRPC, but stimulated a marked increase in adrenal androgens
(Taplin et al., 2008). From these ﬁndings the authors hypothesized
that inhibition of glucocorticoid receptors by mifepristone might
lead to an increase in adrenocorticotropic hormone followed by
an increase in adrenal androgens, and that their conversion by
tumor cells to testosterone and DHT might have limited the efﬁ-
cacy of mifepristone.As stated by Taplin et al. (2008), a therapeutic
approach that combines mifepristone with a second drug harbor-
ing a complementary mechanism might be effective in blocking
the compensatory rise in adrenal androgens seen in patients with
CRPC. These data clearly demonstrate the impact of inﬂammation
and gonadal hormones in tumor progression thus consolidating
the fundamental work of Rudolf Virchow and George Thomas
Beatson in the ﬁeld of tumor-associated inﬂammation.
INFLAMMATION AND RADIATION
Several lines of evidence indicate that inﬂammation plays a pivotal
role in modulating radiation responsiveness of tumors. Radi-
ation treatment is obviously a two-edged sword. On the one
hand, sublethal doses of ionizing radiation (IR) induces a nuclear
DNA damage response. On the other hand, they trigger a cellular
damage response in tumors by inducing pro-inﬂammatory path-
ways predominantly mediated via activation of NF-κB, the central
linker between inﬂammation, carcinogenesis, and radioresistance.
Apart from NF-κB activation, radiation activates/up-regulates the
expression of immediate early genes encoding for, e.g., c-Fos, c-
Myc, c-Jun (Hong et al., 1997) as well as TNF (Zhou et al., 2001),
GM-CSF (Akashi et al., 1992), PGHS-2 (Steinauer et al., 2000),
and ICAM-1 (Son et al., 2006). Radiation also induces activation
of receptor tyrosine kinase pathways (Fedrigo et al., 2011) and
mitochondria-associated responses (Aykin-Burns et al., 2011). As
demonstrated byValerie et al. (2007), radiation-induced activation
of plasma membrane receptors occurs via generation of ioniz-
ing events in the liquid phase of the cytosol that are ampliﬁed,
possibly via mitochondria, generating large amounts of ROS and
RNS that inhibit protein tyrosine phosphatase (PTPase) activi-
ties. Moreover, radiation activates acidic sphingomyelinase and
increases the production of ceramide. Inhibition of PTPases leads
to activation of non-receptor and receptor tyrosine kinases (RTK)
including epidermal growth factor receptor (EGFR) and the acti-
vation of down-stream signal transduction pathways (Goldkorn
et al., 1997; Szumiel, 2008). Radiation-induced ceramide was
found to promote membrane-associated receptor activation by
facilitating the clustering of receptors within lipid rafts (Maziere
et al., 2001; Galabova-Kovacs et al., 2006). As a consequence, acti-
vated RTK induce down-stream pro-survival pathways (e.g., Akt)
that might act as promising targets in enhancing radiosensitivity
of tumors.
Furthermore, various inﬂammatory mediators are reported as
being up-regulated during radiation responses. In humanglioblas-
toma cells, exposure to gamma-irradiation stimulated release of
IL-6 and IL-8 into culture supernatants (Pasi et al., 2010). Radia-
tion and chemotherapy led to a remarkable increase in the produc-
tion of these cytokines in human oral carcinoma cells (Tamatani
et al., 2004). IR induced a tremendous increase in IL-1, IL-6, and
GM-CSF production by human lung cancer cells (Zhang et al.,
1994). A similar effect was observed in patients with head and neck
cancer where increased IL-6 and IL-8 levels can be detected after
chemoradiotherapy (Meirovitz et al., 2010). Elevated IL-6 serum
levels are also reported in patients with locally advanced non-small
cell lung cancer undergoing concurrent chemoradiation therapy
(Wang et al., 2010).
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Some concern had been raised about the effect of IR on the
expression of the pleiotropic cytokine TNF. The majority of the
studies points to an activatory action of IR. For instance, Chendil
et al. (2004) reported on a radiation-induced up-regulated TNF
protein in prostate cancer cells PC-3 leading to an increase in
NF-κB activity followed by an induction of Bcl-2 protein. Fur-
thermore, IR persistently induced NF-κB DNA-binding activity
and NF-κB-dependent TNF transactivation and secretion (Veer-
araghavan et al., 2011a). In contrast, three-dimensional conformal
blocking radiation therapy did not alter serum levels of TNF
in patients with prostate cancer (Lopes and Callera, 2011). It is
interesting to note that in an immunocompetent animal model
of pancreatic cancer the combination of the radio inducible TNF-
expressing adenovectorAd.Egr-TNFwith IR resulted in signiﬁcant
anti-tumor effects mediated by the immune system (Meng et al.,
2010). As demonstrated in this study, Ad.Egr-TNF/IR therapy
contributed to local tumor control through TNF production in
the tumor microenvironment. TNF induced expression of the
known potent immune regulator IFN-β that, in turn, stimu-
lated the production of chemokines leading to the recruitment
of CD8+ T cells to the tumor. Several clinical and preclini-
cal studies with Ad.Egr-TNF/IR have suggested that this local
approach suppresses the growth of distant metastases (Moral and
Tomillero, 2008). However, a Phase III trial comparing Ad.Egr-
TNF (TNFerade™) along with standard of care therapy (deﬁned
as infusion 5-FU and radiation therapy, followed by gemcitabine
or gemcitabine/erlotinib maintenance therapy) versus standard of
care therapy in the treatment of locally advanced, unresectable
pancreatic cancer failed. Since the interim analysis did not pro-
vide sufﬁcient evidence of the clinical effectiveness of TNFerade,
the supplying company, GenVec, announced the discontinuation
of the trial in 2010. From these observations one can hypoth-
esize that up-regulated TNF probably enhances the impact of
tumorigenic stimuli within the tumor or the tumor microenvi-
ronment thereby forcing a critical ampliﬁcation mechanism in
tumor-associated inﬂammation triggered by pro-inﬂammatory
mediators.
It should be kept in mind that radiation therapy represents
an efﬁcient local anti-cancer approach leading to elimination of
both, tumor cells and cells of the tumor microenvironment such
as endothelial cells and tumor-induced suppressor T cells (North,
1984). IR also affects function of immune cells culminating in
homing of APC and effector T cells (Ganss et al., 2002). According
to the study of Ganss et al. (2002), the combination of irradiation
and adoptive tumor-speciﬁc T cell therapy ensures antigen-driven
tumor cell eradication with anti-angiogenic effects on tumor
endothelium. It has been shown previously that sublethal doses of
IR stimulates anti-tumor T cell responses and up-regulates MHC
class I/II expression in melanoma cells rendering the cells more
sensitive to T cell recognition (Abdel-Wahab et al., 1996), obvi-
ously through tumor-speciﬁc antigen presentation byDC (Ciernik
et al., 1999). Clinical phase I/II trials are ongoing and will shed
light on the efﬁciency of low-dose single phase fraction radio-
therapy on tumor-inﬁltrating T cells responses in patients with
liver metastasis derived from colorectal caner (Reissfelder et al.,
2011) and primarily operable pancreatic cancer (Timke et al.,
2011).
PGHS-2 INHIBITION
PGHS-2, the rate-limiting enzyme involved in converting arachi-
donic acid to prostanoids, has emerged as another crucial NF-κB-
dependent pro-inﬂammatory mediator in tumorigenesis. Aber-
rant up-regulation of PGHS-2 is frequently observed in vari-
ous pre-cancerous and malignant tissues. Because most of the
PGHS-2-induced effects are mediated by its product PGE2, down-
regulation of prostaglandins in tumor tissues by PGHS-2 inhibi-
tion blocks several neoplastic pathways restricting tumor growth.
Radiation is known to induce inﬂammation and NF-κB conse-
quently up-regulating/activating PGHS-2. In this context, PGHS-
2 inhibitors have been tested for their anti-tumor efﬁciency in
combination with radiation or chemotherapy. It was found that
these inhibitors exert promising anti-cancer effects in a variety
of human tumor cells and increase the sensitivity of tumor cells
toward chemotherapy and/or radiation therapy. For instance, the
PGHS-2 inhibitorNS398 enhanced the radiosensitivity of radiore-
sistant esophageal cancer cells CSC-like Eca109R50Gy most likely
by down-regulating the expression of β-catenin as well as inhibit-
ing activation of Akt and inducing apoptosis (Che et al., 2010,
2011). NS398 was also found to radiosensitize human melanoma
cells through G2/M arrest of the cell cycle, predominantly via
necrotic mechanisms (Johnson et al., 2008). A further PGHS-2
inhibitor, celecoxib, increased radiation-induced cell death, and
clonogenic kill of prostate cancer cells in vitro providing a rationale
for clinical evaluation of celecoxib in combination with irradia-
tion in prostate cancer patients (Handrick et al., 2009). Celecoxib
also enhanced radiosensitivity of bronchial and colon carcinoma
cells by inhibiting EGFR-mediated mechanisms of radioresis-
tance independent of PGHS-2 activity implying that PGHS-2
inhibition might ameliorate the therapeutic outcome of radia-
tion therapy even in patients with PGHS-2-independent tumor
radioresistance (Dittmann et al., 2008). In line with this obser-
vation, targeting PGHS-2 by different pharmacological inhibitors
led to radio enhancement of human glioma cells in the absence of
the PGHS-2 protein (Kuipers et al., 2007). Nimesulide is another
PGHS-2-selective inhibitor that has been found to increase the
efﬁcacy of radiation therapy in non-small cell lung cancer cells
possibly via suppression of NF-κB-mediated, radiation-induced
cytoprotective genes (Grimes et al., 2006).
However, selective PGHS-2 inhibitors have come under
scrutiny because of reports suggesting an increased cardiovas-
cular risk associated with their use (Solomon et al., 2008). The
thitherto used high therapeutic concentrations of these drugs
may contribute to a pro-thrombotic state in patients with higher
risk for serious cardiovascular events. A novel approach to over-
come the limitations associated with the toxicity of PGHS-2
inhibitors might be the combination of pharmacological PGHS-
2 inhibitors at low doses with naturally occurring compounds
such as the catechin EGCG which is a promising chemopreventive
agent derived from green tea (Cerella et al., 2010; Härdtner et al.,
2012). Of note, nutraceuticals such as plant-derived polyphenols
have been studied intensively for their potential chemopreven-
tive properties and have been found as being pharmacologically
safe. These compounds comprise genistein, curcumin, resvera-
trol, silymarin, caffeic acid phenethyl ester, ﬂavopiridol, emodin,
green tea polyphenols (e.g., EGCG), piperine, oleandrin, ursolic
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acid, and betulinic acid. These phytochemicals sensitize tumor
cells to chemotherapeutic agents and radiation therapy by inhibit-
ing pathways responsible for treatment resistance (Garg et al.,
2005; Nambiar et al., 2011). Among them, curcumin derived
from the rhizomes of Curcuma longa has been identiﬁed to
improve the anti-tumor effects of IR by blocking NF-κB path-
ways, down-regulating anti-apoptotic Bcl-XL and survivin as well
as increasing G2/M phase arrest in the cell cycle distribution
in Burkitt’s lymphoma cells (Qiao et al., 2012). Curcumin also
potentiates radiation therapy-induced cell death by targeting radi-
ation therapy-induced NF-κB activation in pancreatic cancer cells
(Veeraraghavan et al., 2011b).
STAT-3 AND HIF-1 INHIBITION
Apart from NF-κB and PGHS-2, STAT-3 is a further inﬂammatory
molecule crucially involved in radioresistance of tumors. Since
enhanced radioresistance of cancer cells is additionally related to
radiation-induced activation of the JAK/STAT pathway, inhibition
of STAT by, e.g., phytochemicals might sensitize tumors to radia-
tion therapy. It has been shown previously that STAT-3-mediated
radiosensitization obviously occurs via down-regulation of anti-
apoptotic survivin (Kim et al., 2006a). In this context, resveratrol,
a polyphenolic phytoalexin, selectively targets numerous cell sig-
naling pathways and decreases clonogenic survival primarily via
an apoptotic mechanism. In melanoma cells, resveratrol inhibits
STAT-3 and NF-κB-dependent transcription, culminating in sup-
pression of c-FLIP and Bcl-XL expression, while activating the
MAPK and the ATM-Chk2-p53 pathways (Johnson et al., 2008).
Resveratrol alsoup-regulatesTRAILpromoter activity and induces
TRAIL surface expression in some melanoma cell lines, resulting
in a rapid apoptosis development (Johnson et al., 2008). As also
demonstrated in this study, sequential treatment of melanoma
cells, ﬁrst with gamma-irradiation to up-regulate TRAIL recep-
tor surface expression, and then with resveratrol to suppress
anti-apoptotic proteins c-FLIP and Bcl-XL and induce TRAIL
surface expression, dramatically up-regulated apoptosis in some
melanoma cell lines. Nitidine chloride, a natural phytochemical
alkaloid derived from Zanthoxylum nitidum, was identiﬁed as a
potent STAT-3 signaling inhibitor suppressing angiogenesis and
growth of human gastric cancer (Chen et al., 2012a). From these
data one canhypothesize that phytochemicals in combinationwith
IR may play a signiﬁcant role in enhancing the therapeutic efﬁcacy
of cancer treatment.
As already mentioned, HIF-1, the key mediator in hypoxia sig-
naling pathways, is crucially involved in hypoxia-induced tumor
radioresistance. This obviously includes radiation-induced acti-
vation of HIF-1 (Moeller et al., 2004; Harada et al., 2009a,b),
HIF-1-dependent induction of VEGF and protection of endothe-
lial cells from radiation-induced cytotoxicity by VEGF (Gorski
et al., 1999) as well as delivery of oxygen and nutrients to tumor
cells by radioprotected tumor blood vessels (Zeng et al., 2008).
N-Myc down-stream-regulated gene 2 (NDRG2) was recently
identiﬁed in cervical cancer cells as a new HIF-1 target gene acting
down-stream of HIF-1 to promote radioresistance via suppression
of radiation-induced Bax expression (Liu et al., 2010). There-
fore, it would be reasonable to study the efﬁcacy of HIF-1 and
NDRG2 blockage as radiosensitizer for tumor therapy. Strategies
to over-come radioresistance of hypoxic tumor cells comprise,
among others, hyperbaric oxygenation, gene therapy approaches,
fractionated radiotherapy, radiosensitization by mimicking the
effect of molecular oxygen using nitroimidazole derivates as well
as suppression of hypoxic tumor cell radioresistance by HIF-1
inhibitors (for a review, see Harada, 2011). As described pre-
viously, administration of the HIF-1 inhibitor YC-1 to hypoxic
cobalt-treated cells derived from squamous-cell carcinoma of the
larynx effectively inhibited HIF-1α expression, and enhanced the
sensitivity of cells to radiation, decreasing the surviving fraction
to that of normoxic cells (Moon et al., 2009). YC-1 was found to
reduce the number of tumor lesions after tumor cell inoculation
in nude mice (Shin et al., 2007). Compared to radiation therapy
alone, inhibition of radiation-induced HIF-1 activation by YC-1
led to a signiﬁcant reduction in tumor cell growth (Harada et al.,
2009b).
Another HIF-1 inhibitor, acriﬂavine, was found to inhibit
tumor growth and angiogenesis in a xenograft tumor model for
human prostate cancer through blockage of HIF-1 dimerization
(Lee et al., 2009). Since the same agent blocked lung metastasis in
an orthotopic breast cancer model (Wong et al., 2012), it would
be of interest to test the efﬁcacy of this HIF-1 inhibitor in increas-
ing radioresistance of certain tumors. Interestingly, inhibition of
Hsp90 function by 17-allylamino-17-demethoxygeldanamycin or
deguelin, a novel natural inhibitor of Hsp90, suppressed increases
in HIF-1α/Hsp90 interaction and HIF-1α expression in radiore-
sistant lung cancer cells (Kim et al., 2009). Hsp90 interacts with
HIF-1α in competition with receptor of activated protein C kinase
1 (RACK-1) and inhibits oxygen-independent degradationof HIF-
1α (Semenza, 2007). The study by Kim et al. (2009) also demon-
strated that the combined treatment of radiation with deguelin
signiﬁcantly decreased the survival and angiogenic potential of
radioresistant lung cancer cells in vitro and inhibited tumor growth
and angiogenesis in vivo.
Even phytochemicals have the capacity to inhibit radiation-
induced HIF-1 activation. Pre-treatment of prostate cancer cells
with soy isoﬂavones inhibited Src/STAT-3/HIF-1α activation by
radiation and nuclear translocation of HIF-1α. These ﬁndings
correlated with decreased expression of APE1/Ref-1 and DNA-
binding activity of HIF-1α and NF-κB (Singh-Gupta et al.,
2009). Apurinic/apyrimidinic (AP) endonuclease 1/redox factor-1
(APE1/Ref-1) is a multifunctional protein involved in DNA repair
that also functions as a redox activator of cellular transcription fac-
tors. Emodin, a natural anthraquinone enriched in the traditional
Chinese herbal medicines and novel small HIF-1 inhibitor, was
found to improve efﬁcacy of chemotherapeutic drugs by inhibit-
ing transactivation of HIF-1 without impairing mRNA expression
and stability of HIF-1α protein in prostate cancer cells (Huang
et al., 2008). Another approach to HIF-1 blockage might be the
use of cell-permeable HIF-1 antagonists (Shi et al., 2007). As
mentioned before, HIF-1 contributes to tumor radioresistance
by up-regulating survivin expression under hypoxic conditions.
Moreover, in hypoxic tumor cells the HIF-1 signaling pathway
is activated and could be further enhanced by radiation, thereby
providing survival signals to adjacent vascular endothelial cells
by up-regulation of VEGF and basic ﬁbroblast growth factor
(bFGF) and resulting in tumor radioresistance through vascular
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radioprotection. Thus, HIF-1 antagonists might decrease tumor
angiogenesis and sensitize tumor cells to radiotherapy.
Targeting HIF-1 for radiosensitization can also be achieved
by inhibiting its up-stream mediators. In this respect, the
PI3K/Akt/mTOR pathway can be considered as the most rel-
evant target in sensitizing tumors to radiation therapy. Muta-
tions in this pathway can be found in various human can-
cers and have been found to up-regulate HIF-1α expression
(Zhong et al., 2000). The PI3K/Akt/mTOR pathway also affects
the NF-κB-mediated expression of PGHS-2 (Yang et al., 2009)
and radiation-induced MMP-9 expression (Cheng et al., 2006).
Several studies demonstrated that speciﬁc blockage of this path-
way by certain inhibitors such as erufosine (Rudner et al.,
2010), LY294002 (Nakamura et al., 2005; Kao et al., 2007),
RAD001 (Albert et al., 2006), and rapamycin (Majumder et al.,
2004) ensures efﬁcient radiosensitization of distinct tumors
cells.
NF-κB INHIBITION
In recent years NF-κB inhibition by synthetic compounds as
well as nutraceuticals of different sources has been approved for
tumor radiosensitization. In particular the use of nutraceuticals
became a popular approach due to the broad anti-tumor and
anti-inﬂammatory properties in conjunction with low toxicity
risks of these compounds (Deorukhkar et al., 2007; Deorukhkar
and Krishnan, 2010). How these drugs block NF-κB activation
is becoming increasingly apparent. Among them, curcumin has
emerged as one of the best studied plant-derived polyphenols.
In a phase II clinical trial curcumin showed beneﬁcial effects in
patients with advanced pancreatic cancer (Dhillon et al., 2008).
Curcumin down-regulated expression of NF-κB, PGHS-2, and
phosphorylated STAT-3 in peripheral blood mononuclear cells
from these patients. Furthermore, curcumin has been shown to
suppress TNF-mediated NF-κB activation by inhibiting inhibitor
of kappaB alpha (IκBα) in human myeloid ML-1a cells (Singh and
Aggarwal, 1995). Curcumin also confers radiosensitizing effects in
prostate cancer cells by inhibiting TNF-mediated NF-κB activa-
tion resulting in Bcl-2 protein down-regulation and concomitant
activation of cytochrome c and caspase-9 and -3 (Chendil et al.,
2004). More recently, curcumin was found to sensitize colorec-
tal cancer cells to radiotherapy by suppressing radiation-induced
NF-κB activation via inhibition of radiation-induced phosphory-
lation and degradation of IκBα, inhibition of inhibitor of kap-
paB kinase (IKK) activity, and inhibition of Akt phosphorylation
(Sandur et al., 2009) consequently leading to down-regulation
of several tumorigenic factors in colorectal cancer xenografts in
nude mice (Kunnumakkara et al., 2008). Apart from its IKK-
inhibitory capacity, curcumin also blocks p65 phosphorylation
and acetylation and represses the p300/CREB-binding protein
(CBP) HAT activity-dependent transcriptional activation from
chromatin (Balasubramanyam et al., 2004). Similarly, anacardic
acid (6-pentadecylsalicylic acid) derived from traditional medi-
cinal plants, such as cashew nuts, has been identiﬁed to inhibit
NF-κB activation, to suppress the activation of IκBα kinase that
led to abrogation of phosphorylation and degradation of IκBα and
to inhibit acetylation and nuclear translocation of p65 (Sung et al.,
2008). The same study demonstrated that down-regulation of the
p300 HAT gene by RNA interference abrogated the effect of anac-
ardic acid on NF-κB suppression. Further nutraceuticals including
the soy isoﬂavone genistein (Raffoul et al., 2006), the isoquinoline
alkaloid berberine from medicinal plants such as Berberis aris-
tata, Coptis chinensis, Coptis japonica, Coscinium fenestratum, and
Hydrastis canadensis (Pandey et al., 2008), piceatannol (3,3′,4,5′-
trans-trihydroxystilbene), a naturally occurring hydroxylated ana-
log of resveratrol found in various plants (Son et al., 2010), the
principal prenylated ﬂavonoid xanthohumol from Humulus lupu-
lus (Harikumar et al., 2009), and the polyphenol butein (3,4,2′,4′-
tetrahydroxychalcone) from Rhus verniciﬂua Stokes (Pandey et al.,
2007) have been identiﬁed as blocking NF-κB by direct inter-
action with IKKβ on cysteine 179 residue. NF-κB inhibition by
direct interaction with one of its subunits occurs in the presence
of numerous phytochemicals including sesquiterpene lactones
(Garcia-Pineres et al., 2001). In radiation-resistant human CGL1
cells, parthenolide, a major active component of the herbal medi-
cine feverfew (Tanacetum parthenium), enhanced radiosensitivity
through NF-κB inhibition and apoptosis induction via p53 stabi-
lization, induction of pro-apoptotic Bax, and phosphorylation of
pro-apoptotic Bid (Mendonca et al., 2007). The radiosensitization
effect of parthenolide is enhanced in the presence of tumor sup-
pressor protein PTEN (phosphatase and tensin homolog deleted
on chromosome 10), in part, by suppressing the absolute amount
of activated p-Akt in human prostate cancer cells (Sun et al., 2007).
The group of Aggarwal recently found out that crotepoxide (a sub-
stituted cyclohexane diepoxide), isolated from Kaempferia pulchra
(peacock ginger), inhibited activation of TGF-β-activated kinase
(TAK)-1, which led to suppression of IκBα kinase, abrogation of
IκBα phosphorylation and degradation, nuclear translocation of
p65, and suppression of NF-κB-dependent reporter genes encod-
ing for anti-apoptotic (Bcl-2, Bcl-XL, IAP1/2, Mcl-1, survivin,
TRAF-1), pro-apoptotic (Bax, Bid), pro-inﬂammatory (PGHS-2),
proliferation- (cyclin D1, c-Myc), invasion- (ICAM-1, MMP-9),
and angiogenesis-promoting (VEGF) factors (Prasad et al., 2010).
Moreover, Tamatani et al. (2007) analyzed the effects of radiation
therapy in combination with cepharanthine on NF-κB activation
and expression of its down-stream effector molecules in human
oral squamous-cell carcinoma cells. Cepharanthine is a biscoclau-
rine alkaloid extracted from the roots of Stephania cepharantha
Hayata, and is widely used in Japan for the treatment of patients
with leucopenia, nasal allergy, and venomous snakebites. The
authors could show that treatment of cancer cells with cepharan-
thine combined with exposure to IR enhanced radiosensitivity via
NF-κB inhibition and concomitant down-regulation of IL-6, IL-8,
and anti-apoptotic proteins such as cellular inhibitor of apopto-
sis protein (cIAP)-1 and -2. Moreover, the pleiotropic effects of
cepharanthine also includes inhibition of STAT-3 in the human
osteosarcoma cell line SaOS2 (Chen et al., 2012b). These examples
highlight the crucial role of naturally occurring compounds in
targeting inﬂammatory signaling pathways for sensitizing tumors
to radiation therapy. Beside them, a variety of further compounds
have been identiﬁed to enhance radiosensitivity via inhibition of
NF-κB including celecoxib (Raju et al., 2005), pitavastatin (Tsuboi
et al., 2009), docosahexaenoic acid (Zand et al., 2008), and the
novel organoselenium thioredoxin reductase inhibitor ethaselen
(Wang et al., 2011).
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TUMOR CELL RE-POPULATION
It is commonly accepted that aggressive radio-/chemotherapy
often results in a negative selection toward highly aggressive tumor
clones. In recent days, the induction of radiation-induced apopto-
sis, the principal purpose of radiation therapy, has come under
scrutiny due to reports suggesting that dying tumor cells use
the apoptotic pathway to stimulate the re-population of tumors
subjected to radiation therapy. The process of re-population was
originally discovered in the second half of the twentieth century
and is commonly accepted as playing a crucial role in radio-/
chemotherapy (Hermens and Barendsen, 1969; Stephens et al.,
1978). Interestingly, the group of Li from Aurora (USA) demon-
strated that radiation-induced apoptosis comprises caspase-3
cleavage and concomitant activation of Ca2+-independent phos-
pholipase A2 (iPLA2) followed by PGE2 release promoting tumor
cell re-population in vitro and in vivo (Huang et al., 2011). The
relevance of this mechanism for the caspase-mediated tumor cell
re-populationwas conﬁrmedby caspase-3 determination indiffer-
ent cancer patients. Herein, elevated expression levels of activated
caspase-3 in tumor tissues correlated with poor clinical outcome
in patients with head and neck cancer as well as advanced stage
breast cancer. However, the contribution of macrophages and
the subsequently generated clearance-related anti-inﬂammatory
milieu to radiation-induced tumor cell re-population and poor
therapeutic outcome should be taken into consideration. As dis-
cussed byTauber and co-workers, apoptoticmanifestations such as
externalization of phosphatidylserine, bleb formation, and DNA
fragmentation are crucially involved inmacrophage activation and
dependon caspase-3 activation (Jänicke et al., 1998;Coleman et al.,
2001; Sebbagh et al., 2001). The authors conclude that caspase-3-
positive apoptotic cells can recruit more macrophages and are
more efﬁciently internalized by the phagocytes (“silent clear-
ance”) culminating in a strong anti-inﬂammatory and growth-
promoting phagocyte response via release of clearance-associated
cytokines, e.g., PGE2 than their caspase-3-negative counterparts.
However, further preclinical and clinical studies using certain cas-
pase inhibitors are required to strengthen this hypothesis. In this
context, the novel caspase inhibitor GS-9450 was found to down-
regulate caspase-3 expression on peripheral T cells from chroni-
callyHCV-infected patients in a phase II clinical trial (Arends et al.,
2011). It would therefore be of interest to study a putative beneﬁ-
cial effect of a combinatorial treatmentwith caspase inhibitors and
radiation therapy on the clinical outcome of patients with various
advanced cancer types.
PATTERN RECOGNITION RECEPTORS IN RADIOIMMUNITY
It is well known that chronic inﬂammation induced by non-
infectious agents can also contribute to carcinogenesis and act
as a driving force in tumorigenesis. Several factors such as
growth factors, oncoproteins, and toxins can affect the host via
an activation of pattern recognition receptors (PRR) interacting
with exogenous pathogen-associated molecular patterns (PAMP;
Kawai and Akira, 2011). Apart from PAMP, the same receptor
superfamily also recognizes endogenous “alarmins” both of them
comprising the group of danger-associated molecular patterns
(DAMP; Bianchi, 2007). Receptor ligation leads to activation of
inﬂammatory cells and initiation of host responses that tend to
eradicate invading microorganisms (Akira et al., 2006; Karin et al.,
2006). Not surprisingly, inadequate pathogen elimination, recur-
ring tissue injury, prolonged inﬂammatory signaling, and failure
of anti-inﬂammatory mechanisms can all culminate in chronic
inﬂammation promoting cancer development.
Signaling via PRR alsomakes an impact on radiation responses.
It has been shown previously that both, low (0.075 Gy) and high
(2 Gy) doses of IR causes sustained stimulation of IL-12 and IL-18
secretion bymousemacrophages (Shan et al., 2007)with concomi-
tant activation of NF-κB accompanied by elevated cytoplasmic
MyD88 levels and an up-regulated surface expression of CD14 and
TLR-4/MD-2 (Shan et al., 2007), the latter acting as LPS sensor.
From these ﬁndings the authors hypothesized that IR can stim-
ulate the secretion of IL-12 and IL-18 presumably via activation
of the Toll signaling pathway in macrophages. A detailed descrip-
tion of the TLR-4 signaling pathway is visualized schematically in
Figure 2.
Interestingly, RP105 (radioprotective 105 kDa), a TLR-related
molecule, was recently identiﬁed on human B cells and DC
(Fugier-Vivier et al., 1997) and characterized as being similar to
TLR-4 in that the extracellular leucine-rich repeats associate with
MD-1, an MD-2-like molecule (Miyake et al., 1995; Fugier-Vivier
et al., 1997). MD-2 directly binds to lipid A, the active center of
lipopolysaccharide (LPS), leading to dimerization of TLR-4/MD-
2 (Ohto et al., 2011). An antibody raised against surface-bound
RP105 was found to drive B cell proliferation and protection
from subsequent radiation- or dexamethasone-induced apoptosis
(Miyake et al., 1994). Studies by Divanovic et al. (2005) demon-
strated that: (a) RP105 is a speciﬁc inhibitor of TLR-4 signaling in
human embryonal kidney cells HEK293; (b) RP105/MD-1 inter-
acts directly with TLR-4/MD-2, thus abolishing the LPS-binding
capacity of the complex; (c) RP105 regulates TLR-4 signaling in
DC and macrophages; and (d) RP105 regulates in vivo responses
to LPS supporting the assumption that RP105 acts as a physio-
logical negative regulator of TLR-4 responses. This brief overview
makes it clear that, on the one hand, pro-inﬂammatory responses
to radiation and TLR signaling enhance the impact of tumori-
genic factors in the tumor and the tumor microenvironment and,
on the other hand, might represent pivotal target structures in
radiation therapy. As discussed by Schaue and McBride (2010),
radiation-induced DAMP signaling via TLR-2/-4 has emerged as
a critical component in affecting the outcome of anti-cancer ther-
apies. In this context, radiation was found to induce secretion of
the prototypical DAMP, the high-mobility-group box 1 (HMGB-
1)“alarmin”protein fromdying tumor cells as a prerequisite for the
development of a tumor antigen-speciﬁc T cell immunity medi-
ated by an interaction of HMGB-1 with TLR-4 on DC (Apetoh
et al., 2007). The same study revealed that patients with breast
cancer who carry a TLR-4 loss-of-function allele relapsed more
quickly after radiotherapy and chemotherapy than those carrying
the normal TLR-4 allele implying a clinically relevant immunoad-
juvant pathway triggered by tumor cell death. An intriguing novel
ﬁnding comprises the reduction of metastatic ability and MMP-
9 expression in MGC-803 gastric cancer cells by silencing of the
HMGB-1 expression using an HMGB-1-speciﬁc RNAi lentiviral
vector (Song et al., 2012). As also shown in this study, HMGB-
1 silencing decreased cell proliferation and sensitized cells to
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FIGURE 2 |TLR-4 signaling in cancer.TheTLR-4/MD-2 receptor complex
recognizes and binds exogenous PAMP (e.g., endotoxins such as LPS) as
well as endogenous alarmins (HMGB-1, hyaluronan, heat shock proteins).
Release of DAMP into the extracellular space is achieved by a number of
different mechanisms including (i) leakage from necrotic cells, (ii)
increased synthesis and post-translational modiﬁcation in response to
inﬂammation, and (iii) degradation of inactive precursors into TLR-mimetic
degradation products in inﬂammatory environments (Mencin et al., 2009).
TLR-4 induces two distinct signaling pathways controlled by the
TIRAP/MyD88 andTRAM/TRIF pairs of adaptor proteins, which elicit the
production of pro-inﬂammatory cytokines and type I interferons,
respectively. The cytosolic adapter molecules mentioned above comprise
myeloid differentiation protein 88 (MyD88), Toll/IL-1R resistance
domain-containing adapter inducing IFN-β (TRIF), TIR domain-containing
adapter protein (TIRAP), andTRIF-related adaptor molecule (TRAM). TIRAP
is also termed Mal (MyD88 adaptor-like), TRIF is also known asToll/IL-1R
homology domain-containing adaptor molecule 1 (TICAM-1), whereas
TRAM is alternatively entitled TIR-containing protein (TIRP) andTICAM-2,
respectively. TLR-4-mediated signal transduction occurs via
MyD88-dependent and MyD88-independent (i.e., TRAM/TRIF-dependent)
pathways. Both, MyD88-dependent and MyD88-independent pathways
induce expression of genes involved in pro-inﬂammatory and anti-microbial
responses (Akira andTakeda, 2004). In TLR-4 signaling, MyD88
up-regulates inﬂammatory cytokines via NF-κB activation. Moreover, the
MyD88-independent pathway does not only induce inﬂammatory gene
expression in an NF-κB-dependent manner but also up-regulates type I
interferon expression via the transcription factor IRF-3. NF-κB activation
and subsequent inﬂammatory cytokine production are mediated by
different mechanisms and kinetics in the MyD88-dependent and the
MyD88-independent pathway: NF-κB activation in the MyD88-dependent
pathway is an early event occurring with fast kinetics whereas NF-κB
activation via the MyD88-independent pathway represents a late event
occurring with slower kinetics. Unlike TLR-4 signaling in immune cells
which has been found to enhance anti-tumor immunity by, e.g., IL-12/IFN-γ
up-regulation and promotion of DC maturation and function, TLR-4
signaling in cancer cells increases their tumorigenic capacity under certain
circumstances (Oblak and Jerala, 2011). Noteworthy, HMGB-1 which is
released from irradiated tumor cells functions as an endogenousTLR-4
ligand leading to the development of a tumor antigen-speciﬁc T cell
immunity mediated by an interaction of HMGB-1 with TLR-4 on DC.
apoptosis implying HMGB-1 as being a potential target for the
therapeutic intervention of certain cancers such as gastric cancer.
TARGETING OF HEAT SHOCK PROTEINS IN RADIOTHERAPY
A promising approach in cancer therapy also might be target-
ing heat shock proteins (HSP), a class of proteins which are
induced under physiologic stress to promote cell survival in the
face of endogenous or exogenous injury. Compared to normal
cells, tumors frequently have elevated basal Hsp70 levels which
are further enhanced in response to a number of pathological and
environmental stresses such as nutrient deﬁciency, hypoxia, heavy
metals, irradiation, and/or chemotherapeutic agents. Also normal
cells show an increase in the synthesis of Hsp70 following stress in
order to mediate protection against lethal damage and to maintain
protein homeostasis. Screening of nearly 1,000 primary human
tumor biopsies and the corresponding normal tissues revealed
that human carcinomas, but none of the tested normal tissues, fre-
quently present Hsp70 on their cell surface (Multhoff et al., 1995;
Multhoff, 2007). A membrane Hsp70-positive tumor phenotype
has been found to be associated with a signiﬁcantly decreased
overall survival in tumor patients. Therefore, the expression of
this molecule could serve as a negative prognostic marker (Pﬁster
et al., 2007).
Apart from their intracellular localization, Hightower and
Guidon Jr. (1989) reported on an ER/Golgi-independent release
of Hsp70 from viable cells with intact cell membranes already
in the late 1980s. Extracellular HSP are considered as molecules
with immunomodulatory functions (Pockley and Multhoff, 2008;
Pockley et al., 2008) either as cross-presenters of immunogenic
peptides (Srivastava, 1997; Asea et al., 2000) or in a peptide-free
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version as chaperokines (Asea et al., 2002) or stimulators of innate
immune responses (Multhoff et al., 1995). Despite these well-
documented immunological functions, the mechanisms of HSP
export are still controversially discussed since cytosolic HSP lack a
consensus signal for secretion. However, apart from Hsp70, other
molecules lacking a secretory signal such as IL-1α, IL-1β, and
HMBG-1 are also found outside of cells (Nickel and Seedorf, 2008;
Eder, 2009). Hsp70 also has been found to be located on the cell
surface although lacking a transmembrane domain (Multhoff and
Hightower, 1996). Membrane Hsp70 might help to maintain sta-
bility of tumor cells and thus might protect tumors from lethal
damage induced by environmental stress (Horvath et al., 2008;
Horvath and Vigh, 2010). The fundamental work of the group
of Antonio De Maio has demonstrated an interaction of mem-
bers of the HSP70 family with artiﬁcial membranes containing
phosphatidylserine (PS; Arispe and De Maio, 2000; Arispe et al.,
2002; Vega et al., 2008; De Maio, 2011). Our group reported on an
interaction of Hsp70 with the sphingolipid globotriaosylceramide
(Gb3) in the plasma membrane of non-stressed human gastroin-
testinal stromal tumors (Gehrmann et al., 2008). Gb3 is found in
cholesterol-rich microdomains, also termed as lipid rafts, which
serve as signal transduction platforms. Following irradiation or
hypoxia-induced stress Hsp70 was found to be associated pre-
dominantly with PS outside of lipid rafts in the plasma membrane
of tumor cells (Schilling et al., 2009). These data indicate that
environmental stress might result in a re-organization of the lipid
bilayer and might modulate the interaction of Hsp70 with lipid
components. Surprisingly, only tumors but not the correspond-
ing normal tissues were found as being membrane Hsp70-positive
using the IgG1 mouse monoclonal antibody cmHsp70.1. In con-
trast, other Hsp70-speciﬁc antibodies failed to bind to membrane
Hsp70onviable tumor cells (Stangl et al., 2011). Thediscovery that
neither high/low salt concentrations nor changes in the pH were
able to release Hsp70 from the plasma membrane of tumor cells
(Gehrmannet al., 2008;Vega et al., 2008) conﬁrmedourhypothesis
that in tumor cells Hsp70 is an integral membrane protein which
can associate with raft (Gb3) and non-raft (PS) lipid components.
We recently observed an increased surface expression of Hsp70
in colorectal tumor cells after IR alone or in combination with
hyperthermia (HT) while the amount of extracellular Hsp70 was
only increased when HT was given additionally (Schildkopf et al.,
2011). Moreover, a high up-regulation of the co-stimulation mol-
ecule CD80 and the chemokine receptor CCR7 on DC was mea-
sured after contact with supernatants of X-ray plus HT-treated
cells. This was dependent on extracellular Hsp70. Combined treat-
ments further led to signiﬁcantly increased phagocytosis rates of
macrophages and DC and increased pro-inﬂammatory cytokine
(IL-8, IL-12) secretion. From these ﬁndings we conclude that X-
ray combined with HT induces Hsp70-dependent activation of
immune cells and might generate a tumor microenvironment
beneﬁcial for cure.
HSP over-expression in tumor cells plays a pivotal role in
tumorigenesis by inhibiting apoptosis and senescence. Recent
studies indicate an involvement of HSP such as Hsp70/Hsp72 and
Hsp90 in the recognition of PAMP by binding to TLR-4 within
lipid rafts (Triantaﬁlou and Triantaﬁlou, 2004; Wheeler et al.,
2009). Since extracellular residing Hsp70 acts as a danger signal for
the immune system (Matzinger, 1998), this stress protein has been
added to the list of “alarmins” comprising the group of DAMP
together with PAMP, hyaluronan, and other HSP members. Con-
sequently, developing means of abrogating HSP expression may
provide a way to render cancer cells more susceptible to radia-
tion or chemotherapy. Various attempts are underway to target
these proteins, particularly small HSP, in developing potent radi-
ation and chemotherapy sensitizers (Guttmann and Koumenis,
2011). For instance, Hsp27 has been found as being implicated
in the resistance to chemotherapy in several types of cancers.
The group of Moriwaki analyzed the effects of a gemcitabine
treatment in pancreatic cancer cells (Nakashima et al., 2011).
Gemcitabine is an anti-tumor drug and currently considered to
be the standard of care for the treatment of advanced pancre-
atic cancer, but the clinical outcome is still not satisfactory. It was
shown that gemcitabine suppressed growth of pancreatic cancer
cells by inducing apoptosis. Gemcitabine also caused activation of
p38 mitogen-activated protein kinase (MAPK), MAPK-activated
protein kinase 2 (MAPKAPK-2) with concomitant serine phos-
phorylation of Hsp27 at position 15, 78, and 82 without affecting
total Hsp27 levels. From these results the authors conclude that
the phosphorylation status of Hsp27 obviously plays a pivotal role
in gemcitabine-induced growth suppression of pancreatic cancer.
Of Note, the HSP inhibitor KNK437, a benzylidene lactam com-
pound, was observed to dramatically reduce expression of Hsp27
in gemcitabine-resistant pancreatic cancer cells KLM1-R and to
enhance the in vitro anti-tumor cytotoxic effect of gemcitabine
on KLM1-R compared to single-agent gemcitabine (Taba et al.,
2011). KNK437 also sensitizes prostate cancer cells to the apop-
totic effect of hyperthermia by down-regulating heat-induced
Hsp70mRNAexpression (Sahin et al., 2011).Moreover, in patients
with locally advanced squamous-cell esophageal cancer neoadju-
vant radiochemotherapy (NRCT) led to a decreased expression
of Hsp16.2, Hsp90, and heme-binding protein 2 (SOUL), and an
increased Bax/Bcl-2 ratio was found in the responding tumors
(Farkas et al., 2011).
Also Hsp90 may represent a potentially attractive target for
speciﬁc molecular anti-cancer agents, because Hsp90 expression
is up-regulated in tumors as compared with normal tissues,
which implies that tumor cells might be preferentially affected by
Hsp90-targeted therapies (Ferrarini et al., 1992). In this context,
geldanamycin (GA), a naturally occurring ansamycin antibiotic,
along with its clinically used analogs such as 17-allylamino-17-
demethoxygeldanamycin (17-AAG), has been evaluated in pre-
clinical and clinical trials for its signiﬁcant anti-tumor properties.
These agents disrupt Hsp90 association with client proteins by
occupying the nucleotide-binding site of Hsp90 (Grenert et al.,
1997; Prodromou et al., 1997; Stebbins et al., 1997), thereby pre-
venting binding of Hsp90 with ATP and profoundly affecting
the composition of Hsp90-containing multimolecular chaperone
complexes (Obermann et al., 1998;Maloney andWorkman, 2002).
As demonstrated by the group of Gius, treatment of two human
cervical carcinoma cell lines (HeLa, SiHa) with geldanamycin and
17-AAG resulted in cytotoxicity and, when combined with IR,
enhanced the radiation response. In addition,mouse in vivo mod-
els using 17-AAG at clinically achievable concentrations yielded
results that paralleled the in vitro radiosensitization studies of both
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FIGURE 3 | Radiation-induced activation of inflammatory
pathways in tumor cells. Schematical simpliﬁed representation of the
complex intracellular mechanisms leading to radioresistance. Exposure
to ionizing radiation leads to activation of several transcription factors
modulating the expression of numerous factors promoting cancer
development. Novel therapeutic approaches thus aim to interfere with
the activity or expression of these factors, either in single-agent or
combinatorial treatment or as supplements of the existing therapeutic
concepts. Noteworthy, targeting the pro-inﬂammatory signaling
pathways for tumor radiosensitization represents a promising novel
therapeutical approach in cancer. A great variety of classical or novel
drugs including nutraceuticals have the capacity to interfere with the
inﬂammatory network in cancer and are considered as putative
radiosensitizers.
single and fractioned courses of irradiation (Bisht et al., 2003). We
recently analyzed the effects of the novel Hsp90 inhibitor NVP-
AUY922 compared to 17-AAG on the HIF-1α/HIF-2α expression
in combinationwith radiosensitivity in lung cancer cell lines under
normoxic and hypoxic conditions (Schilling et al., 2012b). NVP-
AUY922 is a synthetic, isoxazole/resorcinol-based second genera-
tion Hsp90 inhibitor exhibiting an enhanced metabolic stability
and a tighter binding to Hsp90 compared to 17-AAG (Brough
et al., 2008). As given in our study, both inhibitors reduced basal
and hypoxia-induced HIF-1α levels in EPLC-272H lung carci-
noma cells. However, despite a down-regulation of HIF-1α upon
Hsp90 inhibition, sensitivity toward irradiation remained unal-
tered in EPLC-272Hcells under normoxic andhypoxic conditions.
In contrast, treatment of H1339 lung carcinoma cells with NVP-
AUY922 and 17-AAG resulted in a signiﬁcant up-regulation of
their initially high HIF-1α levels and a concomitant increase in
radiosensitivity indicating the ability of an HIF-1α-independent
radiosensitization of normoxic and hypoxic H1339 lung can-
cer cells via Hsp90 inhibition. From these observations it can
be concluded that treatment strategies combining HSP targeting
and radiochemotherapy appear to be a high potential therapeutic
beneﬁts for cancer patients.
CONCLUDING REMARKS
Although radiation therapy, alone or in combination with
chemotherapy, is the primary treatment for several tumors,
radioresistance dramatically attenuates radiocurability. Several
lines of evidence indicate that inﬂammation plays a pivotal role
in modulating radiation responsiveness of tumors. As discussed
in this review, exposure to IR leads to activation of several tran-
scription factors modulating the expression of numerous factors
promoting cancer development. Novel therapeutic approaches
thus aim to interfere with the activity or expression of these
factors, either in single-agent or combinatorial treatment or as
supplements of the existing therapeutic concepts. Among them,
NF-κB, STAT-3, and HIF-1 play a crucial role in radiation-induced
inﬂammatory responses. A great variety of classical or novel drugs
including nutraceuticals have the capacity to interfere with the
inﬂammatory network in cancer and are considered to function
as putative radiosensitizers (Figure 3). Thus, targeting the inﬂam-
matory signaling pathways induced by IR offers the opportunity to
improve the clinical outcome of radiation therapy by enhancing
radiosensitivity and decreasing putative metabolic effects. Since
inﬂammation and sex steroids also impact tumorigenesis, a thera-
peutic approach targeting glucocorticoid receptors, and radiation-
induced production of tumorigenic factors might be effective in
sensitizing tumor cells to IR in certain cases.
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